KALV
KalVista Pharmaceuticals, Inc.
$26.73
+0.04%
2026-05-08
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Key Fundamentals
Forward P/E
22.27
EPS (TTM)
$-3.94
ROE
-190.2%
Profit Margin
-223.2%
Debt/Equity
1662.33
Price/Book
46.90
Beta
-0.12
Market Cap
$1.42B
Avg Volume (10D)
11.0M
Recent Breakout Signals
No recent breakout signals detected for KALV.
Recent Price Range (60 Days)
60D High
$26.84
60D Low
$14.23
Avg Volume
2.6M
Latest Close
$26.73
Get breakout alerts for KALV
Sign up for Breakout Scanner to receive daily notifications when KALV triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
KalVista Pharmaceuticals, Inc. (KALV) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KALV daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KALV operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.